Clinical trial
A Randomised, Cross-over Study to Compare Quality of Life and Satisfaction in Primary Immunodeficient Patients Treated With Subcutaneous Injections of Gammanorm® 165 mg/mL Administered With Two Different Delivery Devices: Injections Using Pump or Rapid Push
NCT02503293 is registered in ClinicalTrials.gov with Octapharma as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomised, Cross-over Study to Compare Quality of Life and Satisfaction in Primary Immunodeficient Patients Treated With Subcutaneous Injections of Gammanorm® 165 mg/mL Administered With Two Different Delivery Devices: Injections Using Pump or Rapid Push
- Lead sponsor
- Octapharma
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- July 29, 2015
- Completion date
- December 11, 2017
- Enrollment
- 30 (actual)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.
primary immunodeficiency